

Table 1. Twelve-month outcomes among those who completed the study using a frequentist approach.

Outcome	Methotrexate, n = 35; Randomized	Placebo, n = 36; Randomized	p	Treatment Effect (95% CI)
Modified Rodnan skin score, range, 0–78	21.4 ± 2.8 (n = 27)	26.3 ± 2.1 (n = 24)	0.18	–4.9 (–11.9, 2.2)
UCLA skin score, range 0–30	8.8 ± 1.2 (n = 27)	11.0 ± 0.9 (n = 24)	0.15	–2.2 (–5.2, 0.8)
MD global assessment, 10 cm VAS	4.2 ± 0.5 (n = 25)	5.5 ± 0.4 (n = 29)	0.04	–1.3 (–2.7, –0.1)

Values are mean ± standard error of the mean. n is the number with 12-month outcomes. UCLA: University of California Los Angeles; MD: physician; VAS: visual analog scale.